EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Faisabilité de l’administration du carfilzomib en hospitalisation à domicile dans la prise en charge du myélome multiple (étude Carfil-HAD)

Mohamed Touati, Camille Villesuzanne, Gaëlle Maillan, Natalia Dmytruk, Caroline Streicher, Catherine Brillat, Frederica Bompart, Cindy Chauvet, Chantal Tisseuil, Sophie Sardin, Aurélie Perraud, Sophie Bastide und 5 weitere

Bulletin du Cancer · 2026

DOI: 10.1016/j.bulcan.2025.09.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bulletin du Cancer, 2026. Verfasst von Mohamed Touati und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hématologie clinique et thérapie cellulaire, CHU Dupuytren, Limoges, France; Service d'hospitalisation à domicile (HAD), CHU Dupuytren, Limoges, Fran…. Hauptthemen laut MEDLINE: Multiple Myeloma, Oligopeptides, Home Infusion Therapy, Antineoplastic Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The growing number of cancer cases induces increasing pressure on oncology and hematology departments, creating the need for alternatives such as hospitalization at home (HAH). The Carfil-HAD pilot study aimed to assess the feasibility and safety of administering short-duration intravenous carfilzomib infusions at home for the treatment of multiple myeloma. Among the 17 patients included, 15 received 128 infusions of Carfilzomib under a combined Outpatient Hospital (OH)/HAH scheme, are evaluable. Deviations from standard operating procedures were monitored, quality of life and satisfaction were evaluated, and a cost-effectiveness analysis compared the mixed OH/HAH model to exclusive OH care. The results confirmed feasibility: of 128 infusions, 42 were performed in OH and 86 in HAH without serious incident or interruption of care, with 96% of deviations classified as minor. Quality of life is not affected by the mixed care organization, and patient satisfaction was very high. From an economic perspective, the OH/HAH model generated savings of €610 per treatment cycle, nearly half the cost of hospital-based care. In conclusion, intravenous administration of carfilzomib in HAH is feasible and safe. This organization could be applied to other oncological therapies to offer a wider range of outpatient's care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaOligopeptidesHome Infusion TherapyAntineoplastic AgentsHome Care Services, Hospital-BasedHumansMaleQuality of LifeFemaleFeasibility StudiesAgedPilot ProjectsMiddle AgedCost-Benefit AnalysisPatient SatisfactionInfusions, IntravenousHospitalizationAged, 80 and over

Stichwörter der Autor:innen

Analyse médico-économiqueCarfilzomibChemotherapyChimiothérapiesCost-effectiveness analysisHADHAHHospitalisation à domicileHospitalization at homeMultiple myelomaMyélome multiple

Substanzen

carfilzomibOligopeptidesAntineoplastic Agents

Autor:innen und Institutionen

  • Hématologie clinique et thérapie cellulaire, CHU Dupuytren, Limoges, France; Service d'hospitalisation à domicile (HAD), CHU Dupuytren, Limoges, France. Electronic address: mohamed.touati@chu-limoges.fr.
  • Hématologie, CH de Brive, Brive-la-Gaillarde, France.
  • Pharmacie à Usage Intérieur (PUI), CHU Dupuytren, Limoges, France.
  • Hématologie clinique et thérapie cellulaire, CHU Dupuytren, Limoges, France.
  • Pharmacie à Usage Intérieur (PUI), CH de Brive, Brive-la-Gaillarde, France.
  • Service d'hospitalisation à domicile (HAD), relais santé par Relais santé, Hospitalisation à domicile (HAD), Brive-la-Gaillarde, France.

Förderung

  • Amgen Inc

Zitieren

APA

Touati, M., Villesuzanne, C., Maillan, G., Dmytruk, N., Streicher, C., Brillat, C., Bompart, F., Chauvet, C., Tisseuil, C., Sardin, S., Perraud, A., Bastide, S., Lamarsalle, L., Massoulard-Gainant, A., Girault, S., Roussel, M., & Moreau, S. (2026). Faisabilité de l’administration du carfilzomib en hospitalisation à domicile dans la prise en charge du myélome multiple (étude Carfil-HAD). Bulletin du Cancer. https://doi.org/10.1016/j.bulcan.2025.09.005

Vancouver

Touati M, Villesuzanne C, Maillan G, Dmytruk N, Streicher C, Brillat C, et al. Faisabilité de l’administration du carfilzomib en hospitalisation à domicile dans la prise en charge du myélome multiple (étude Carfil-HAD). Bulletin du Cancer. 2026. doi:10.1016/j.bulcan.2025.09.005

BibTeX
@article{Touati2026,
  author = {Touati, Mohamed and Villesuzanne, Camille and Maillan, Gaëlle and Dmytruk, Natalia and Streicher, Caroline and Brillat, Catherine and Bompart, Frederica and Chauvet, Cindy and Tisseuil, Chantal and Sardin, Sophie and Perraud, Aurélie and Bastide, Sophie and Lamarsalle, Ludovic and Massoulard-Gainant, Aude and Girault, Stéphane and Roussel, Murielle and Moreau, Stéphane},
  title = {Faisabilité de l’administration du carfilzomib en hospitalisation à domicile dans la prise en charge du myélome multiple (étude Carfil-HAD)},
  journal = {Bulletin du Cancer},
  year = {2026},
  doi = {10.1016/j.bulcan.2025.09.005}
}
Kostenlos starten →